Surplus stock buyers
By: megans Date of post: 02.06.2017
Secondly, a laboratory study has suggested that Annamycin doesn't succumb to multidrug resistance. Like all other currently approved AML therapies, VYXEOS is also vulnerable to multidrug resistance, thus hindering the oncologist's ability to effectively treat the patient. But if you fail that again, then you are out of luck and on average you will be dead in 6-months...